1. Scrip
  2. >>Focus On Asia

Cell Therapy Developers Dominate China VC/PE Funding In October

 
• By Dexter Jie Yan

Six Chinese biotechs raise a combined $141m in major financing deals backed by venture capital and private equity firms.

funding
Three Chinese cell therapy firms bagged more than $41m in total in October. • Source: Shutterstock

Cell therapy developers took the lion’s share of private equity and venture capital funds raised in China in October, with three firms bagging north of CNY300m ($41m) in total.

On 31 October, Beijing Immunochina Pharmaceuticals Co., Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By Jung Won Shin

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.